Free press releases distribution network?

Agency / Source: Greystone Associates

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Injectable Drug Therapies Expand - Developers Challenged to Improve Safety and Reduce Dosing Says Greystone Associates - Greystone Associates analyzes the market impact and potential of evolving injectable drug technologies
Injectable Drug Therapies Expand - Developers Challenged to Improve Safety and Reduce Dosing Says Greystone Associates

 

PRZOOM - /newswire/ - Amherst, NH, United States, 2010/05/26 - Greystone Associates analyzes the market impact and potential of evolving injectable drug technologies.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Injectable drug formulations designed to improve drug half-life and extend dosing intervals can mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs.

Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug’s release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase. Already a ten billion dollar retail revenue market, the value of injectable drugs with extended dosing regimens will increase nine percent annually through 2013 as new controlled release formulations reach the market.

A new report analyzes the current market and potential for extended release injectables. The report – Sustained Release Injectables: Technologies, Targets and Therapeutics - examines the therapeutic impact of approved sustained release injectable drugs, assesses development-stage candidates, and analyzes key market segments, technology factors, demand drivers and the competitive landscape.

About Greystone
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Greystone Associates

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Injectable Drug Therapies Expand - Developers Challenged to Improve Safety and Reduce Dosing Says Greystone Associates

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Mark Smith - GreystoneAssociates.org 
603-595-4340 mksmith[.]greystoneassociates.org
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Greystone Associates securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Greystone Associates / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com

Visit  Al Rowaad Advocates & Legal Consultants







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today